Amylyx Pharmaceuticals, Inc.
Reports in 10d· 2026-05-07
+9.1% · 90d
$16.88
-0.16 (-0.94%)
After-Hours $16.58(-0.30)
News
(1)April 2026
AMLX reports on Relyvrio commercial launch and neurodegenerative pipeline expansion
AMLXAmylyx Pharmaceuticals, Inc.
# 🧾 What This Document Is This is Amylyx Pharmaceuticals' **Annual Report to Shareholders (ARS)**. Think of it as the company's yearly "state of the union" letter sent directly to its owners (the shareholders). It’s a comprehensive review meant to be more readable than a dense regulatory filing, s
Read summaryView on SEC EDGAR
Peers in Drug Manufacturers - Specialty & Generic
TAK#1
Takeda Pharmaceutical Company Limited
$57.78B-1.07%
ZTS#2
Zoetis Inc.
$50.46B+0.20%
HLN#3
Haleon plc
$43.61B+0.40%
TEVA#4
Teva Pharmaceutical Industries Limited
$36.05B+1.44%
UTHR#5
United Therapeutics Corporation
$25.19B-1.19%
VTRS#6
Viatris Inc.
$15.85B+0.29%
RGC#7
Regencell Bioscience Holdings Limited
$13.93B-2.46%
NBIX#8
Neurocrine Biosciences, Inc.
$13.21B-1.13%
ELAN#9
Elanco Animal Health Incorporated
$11.66B-0.59%
RDY#10
Dr. Reddy's Laboratories Limited
$10.92B+0.15%